Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Return on Equity (2017 - 2023)

Rapid Therapeutic Science Laboratories' Return on Equity history spans 7 years, with the latest figure at 0.02% for Q2 2023.

  • For Q2 2023, Return on Equity fell 119.0% year-over-year to 0.02%; the TTM value through Jun 2023 reached 0.02%, down 119.0%, while the annual FY2022 figure was 0.79%, 332.0% down from the prior year.
  • Return on Equity for Q2 2023 was 0.02% at Rapid Therapeutic Science Laboratories, down from 0.01% in the prior quarter.
  • Across five years, Return on Equity topped out at 9.48% in Q4 2020 and bottomed at 14.4% in Q3 2021.
  • The 5-year median for Return on Equity is 0.26% (2020), against an average of 0.14%.
  • The largest annual shift saw Return on Equity crashed -1719bps in 2021 before it soared 1542bps in 2022.
  • A 5-year view of Return on Equity shows it stood at 0.11% in 2019, then skyrocketed by 8861bps to 9.48% in 2020, then tumbled by -61bps to 3.7% in 2021, then tumbled by -84bps to 0.58% in 2022, then tumbled by -104bps to 0.02% in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Return on Equity are 0.02% (Q2 2023), 0.01% (Q1 2023), and 0.58% (Q4 2022).